[go: up one dir, main page]

UY26832A1 - Uso de cepas de parapoxvirus ovis para la fabricacion de medicamentos antivirales y medicamentos contra el cancer - Google Patents

Uso de cepas de parapoxvirus ovis para la fabricacion de medicamentos antivirales y medicamentos contra el cancer

Info

Publication number
UY26832A1
UY26832A1 UY26832A UY26832A UY26832A1 UY 26832 A1 UY26832 A1 UY 26832A1 UY 26832 A UY26832 A UY 26832A UY 26832 A UY26832 A UY 26832A UY 26832 A1 UY26832 A1 UY 26832A1
Authority
UY
Uruguay
Prior art keywords
drugs
manufacture
parapoxvirus ovis
straps
against cancer
Prior art date
Application number
UY26832A
Other languages
English (en)
Inventor
Gudrun Theiss
Tobias Schlapp
Angela Siegling
Andreas Knorr
Claudia Hirth-Dietrich
Olaf Weber
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10122451A external-priority patent/DE10122451A1/de
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of UY26832A1 publication Critical patent/UY26832A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Surgery (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere al uso de cepas de Parapoxvirus ovis como agente inmonuterapéutico en debilitamientos inmunológicos de naturaleza infecciosa o no infecciosa, así como al uso de cepas de Parapoxvirus ovis para el tratamiento de enfermedades tumorales, infecciones virales y las enfermedades que acompanan a éstas, así como al uso de cepas de Parapoxvirus ovis para la fabricación de medicamentos para el uso en hombres y animales.
UY26832A 2000-07-11 2001-07-11 Uso de cepas de parapoxvirus ovis para la fabricacion de medicamentos antivirales y medicamentos contra el cancer UY26832A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10033582 2000-07-11
DE10122451A DE10122451A1 (de) 2000-07-11 2001-05-09 Verwendung von Stämmen des Parapoxvirus ovis zur Herstellung von antiviralen Arzneimitteln und Arzneimitteln gegen Krebs

Publications (1)

Publication Number Publication Date
UY26832A1 true UY26832A1 (es) 2002-01-31

Family

ID=26006335

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26832A UY26832A1 (es) 2000-07-11 2001-07-11 Uso de cepas de parapoxvirus ovis para la fabricacion de medicamentos antivirales y medicamentos contra el cancer

Country Status (36)

Country Link
US (1) US6685950B2 (es)
EP (1) EP1303286B1 (es)
JP (1) JP5037775B2 (es)
CN (1) CN1455674B (es)
AR (1) AR029954A1 (es)
AT (1) ATE324115T1 (es)
AU (2) AU7063101A (es)
BG (1) BG107448A (es)
CA (1) CA2415397C (es)
CY (1) CY1105408T1 (es)
CZ (1) CZ200371A3 (es)
DE (1) DE50109630D1 (es)
DK (2) DK1303286T3 (es)
EE (1) EE200300018A (es)
ES (1) ES2262663T3 (es)
FI (1) FI20030037A7 (es)
GB (1) GB2381454B8 (es)
HK (1) HK1054329B (es)
HR (1) HRP20030096A2 (es)
HU (1) HUP0400479A3 (es)
IL (1) IL153643A0 (es)
LT (1) LT5079B (es)
LU (1) LU90997B1 (es)
LV (1) LV12990B (es)
MA (1) MA26927A1 (es)
MX (1) MXPA03000279A (es)
NO (1) NO20030082L (es)
NZ (1) NZ523534A (es)
PL (1) PL366397A1 (es)
PT (1) PT1303286E (es)
RU (1) RU2003104525A (es)
SE (1) SE0300034L (es)
SI (1) SI21122A (es)
SK (1) SK362003A3 (es)
UY (1) UY26832A1 (es)
WO (1) WO2002004002A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
US7097842B2 (en) * 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
CN101676389A (zh) * 2000-11-23 2010-03-24 巴法里安诺迪克有限公司 改良安卡拉痘苗病毒变体
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
NZ512341A (en) 2001-06-13 2004-02-27 Bayer Ag Polynucleotides between 15 and 100 base pairs in length coding for parapoxvirus ovis (PPVO)/vaccinia virus recombinant (VVOV) viral genome fragments
EP1499355A4 (en) * 2001-12-07 2005-10-05 Bayer Pharmaceuticals Corp USE OF PARAPOX B2L PROTEIN FOR THE TREATMENT OF CANCER AND THE MODIFICATION OF IMMUNE RESPONSES
AU2003239805B2 (en) * 2002-04-19 2009-09-10 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
ES2305514T5 (es) * 2002-09-05 2019-06-14 Bavarian Nordic As Método para la amplificación de un poxvirus en condiciones exentas de suero
CN1984666A (zh) * 2004-07-13 2007-06-20 爱库里斯股份有限两合公司 与其他抗病毒剂联合治疗hiv/aids的副痘病毒
PT1951274E (pt) * 2005-11-24 2009-12-14 Aicuris Gmbh & Co Kg Parapoxvírus em combinação com agentes quimioterapêuticos citotóxicos clássicos como bioquimioterapia para o tratamento de cancro
JP5004990B2 (ja) * 2009-03-31 2012-08-22 アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物
WO2011072871A1 (en) * 2009-12-18 2011-06-23 Bavarian Nordic A/S Production of ifn-lambda by conventional dendritic cells and uses thereof
JP5699093B2 (ja) * 2012-01-05 2015-04-08 アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフトＡｉＣｕｒｉｓ ＧｍｂＨ ＆ Ｃｏ． ＫＧ パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物
TW201919675A (zh) * 2017-09-07 2019-06-01 德商艾庫瑞斯公司 使用羊副痘疹病毒(Parapoxvirus ovis；PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法
WO2023083943A1 (en) * 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with antivirals
WO2023083950A1 (en) * 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with immunomodulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714665A1 (de) * 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
DE3504940C2 (de) * 1984-02-17 1997-11-06 Bayer Ag Multipotente Paramunitätsmediatoren, Verfahren zu ihrer Herstellung und diese Mediatoren enthaltende Arzneimittel
US5443964A (en) * 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5648101A (en) * 1994-11-14 1997-07-15 Tawashi; Rashad Drug delivery of nitric oxide
JP2000507092A (ja) * 1996-02-28 2000-06-13 バイエル・アクチエンゲゼルシヤフト 外来ｄｎａを含むパラポックスウイルス、それらの製造及びワクチンにおけるそれらの使用
CN1217751A (zh) * 1996-03-29 1999-05-26 奥塔戈大学 副痘病毒载体
ATE203678T1 (de) * 1996-04-15 2001-08-15 Anton Prof Dr Med Vet Dr Mayr Verwendung von multipotenten paramunitätsinducern aus attenuierten, nicht-immunogenen pockenviren oder parapockenviren zur herstellung von arzneimitteln
SE9700617D0 (sv) * 1997-02-21 1997-02-21 Kjell Alving New composition
DE19843222A1 (de) * 1998-09-22 2000-03-30 Hassan Jomaa Verwendung von phosphororganischen Verbindungen zur therapeutischen und prophylaktischen Behandlung von Infektionen
AU775956B2 (en) * 1998-11-02 2004-08-19 Otago Innovation Limited Vascular endothelial growth factor-like protein from ORF virus NZ2 binds and activates mammalian VEGF receptor-2

Also Published As

Publication number Publication date
JP2004517807A (ja) 2004-06-17
LV12990B (en) 2003-08-20
GB2381454A8 (en) 2007-10-23
BG107448A (bg) 2003-11-28
MA26927A1 (fr) 2004-12-20
SE0300034L (sv) 2003-03-03
SI21122A (sl) 2003-08-31
EP1303286B1 (de) 2006-04-26
JP5037775B2 (ja) 2012-10-03
FI20030037L (fi) 2003-03-10
HUP0400479A2 (hu) 2004-06-28
HK1054329A1 (en) 2003-11-28
PT1303286E (pt) 2006-08-31
HUP0400479A3 (en) 2006-02-28
US20030021769A1 (en) 2003-01-30
HRP20030096A2 (en) 2005-02-28
NZ523534A (en) 2005-02-25
EE200300018A (et) 2004-10-15
DK200300015A (da) 2003-03-07
EP1303286A2 (de) 2003-04-23
AU7063101A (en) 2002-01-21
SK362003A3 (en) 2003-07-01
GB2381454A (en) 2003-05-07
WO2002004002A3 (de) 2002-10-31
CN1455674A (zh) 2003-11-12
LT2003009A (en) 2003-08-25
DK1303286T3 (da) 2006-08-28
ATE324115T1 (de) 2006-05-15
AR029954A1 (es) 2003-07-23
HK1054329B (zh) 2005-10-07
NO20030082D0 (no) 2003-01-08
GB0302630D0 (en) 2003-03-12
CA2415397C (en) 2011-04-26
LU90997B1 (en) 2003-01-08
PL366397A1 (pl) 2005-01-24
FI20030037A7 (fi) 2003-03-10
WO2002004002A2 (de) 2002-01-17
CY1105408T1 (el) 2010-04-28
GB2381454B8 (en) 2007-10-23
NO20030082L (no) 2003-01-08
CA2415397A1 (en) 2002-01-17
MXPA03000279A (es) 2004-04-05
CN1455674B (zh) 2019-03-29
ES2262663T3 (es) 2006-12-01
RU2003104525A (ru) 2004-06-27
DE50109630D1 (de) 2006-06-01
US6685950B2 (en) 2004-02-03
IL153643A0 (en) 2003-07-06
CZ200371A3 (cs) 2003-04-16
SE0300034D0 (sv) 2003-01-10
LT5079B (lt) 2003-12-29
GB2381454B (en) 2004-11-24
AU2001270631B2 (en) 2005-07-07

Similar Documents

Publication Publication Date Title
UY26832A1 (es) Uso de cepas de parapoxvirus ovis para la fabricacion de medicamentos antivirales y medicamentos contra el cancer
ECSP056138A (es) Dihidroquinazolinas sustituidas
WO2018190719A3 (en) Anti-sirp alpha antibodies
UY27186A1 (es) Formulación farmacéutica
MX2017014806A (es) Conjugados oligonucleotido- peptido.
UY31106A1 (es) Formulaciones que contienen triazinonas y hierro
CL2017002846A1 (es) Métodos de tratamiento de trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con células t.
WO2015058772A3 (en) Novel hcv culture systems and direct-acting antiviral sensitivity
UY28313A1 (es) Nonadepsipeptidos acilados
AR053775A1 (es) Nonadepsipeptidos acilados ii
DOP2001000211A (es) Uso de cepas de parapoxvirus ovis para la fabricación de medicamentos antivirales y medicamentos contra el cancer
PA8590801A1 (es) Derivados de nucleosido antivirales
BR112021006388A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma infecção viral em um mamífero
ZA200708539B (en) Methods of applying ionization radiation for therapy of HIV infection
CO2023005389A2 (es) Vacuna terapéutica que comprende un antígeno específico de una enfermedad que no afecta al sistema nervioso central y nanopartículas y su uso
PL1765370T3 (pl) Parapoksywirusy w kombinacji z innymi czynnikami przeciwwirusowymi do leczenia HIV/AIDS
WO2003000274A3 (en) Bacteriophage preparation for the treatment of intracellular bacterial infection
CO2022002493A2 (es) Nanoemulsion de ácido 18p-glicirretínico
UY26945A1 (es) Alcanosulfonatos de fenoxifenilo
ATE406888T1 (de) Cyanoacrylat-zusammensetzungen für die therapeutische behandlungvon wunden, die eine revision erfordern
BR0008269A (pt) Uso de uma preparação de m. vaccae, e, método para tratamento de infecção viral crÈnica, excluindo infecção por hiv
Okamoto The 44th Scientific Meeting: Perspectives of Internal Medicine: Virology for Physician∼ Recent Advance in Viral Infection and Treatment∼: 3. Common Viral Infectious Diseases; Viral Hepatitis: 3) Hepatitis A and E
UA59657U (ru) Способ лечения женщин с фоновыми заболеваниями шейки матки на фоне генитальной герпесвирусной инфекции
UY28110A1 (es) Derivados de nucleosido antivirales
DOP2004000891A (es) Nonadepsipeptidos acilados

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20140905